Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod
Therapeutic Advances in Neurological Disorders - United Kingdom
doi 10.1177/1756286418791103
Full Text
Open PDFAbstract
Available in full text
Date
January 1, 2018
Authors
Publisher
SAGE Publications